Metforal

Metformin Hydrochloride, the active ingredient in Metforal, is a Biguanide presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus.

GNH USA supplies Metforal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metforal belongs to the Biguanide class and is indicated for management of hyperglycaemia in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: helps lower fasting and post‑prandial blood glucose levels by improving insulin sensitivity and reducing hepatic glucose output.

Metforal may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: frequent loose stools. - Abdominal discomfort: cramping or pain. - Metallic taste: transient alteration of taste. - Loss of appetite: reduced desire to eat. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Lactic acidosis: life‑threatening accumulation of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes. - Hypoglycaemia (when combined with other glucose‑lowering agents). - Pancreatitis: inflammation of the pancreas. - Anaphylaxis: rare allergic reaction.

Before initiating Metforal, clinicians should evaluate patient‑specific risk factors and monitor relevant clinical parameters.

- Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Hepatic function: evaluate liver enzymes; avoid in active liver disease. - Risk of lactic acidosis: consider contraindications such as hypoxia, sepsis, or alcohol abuse. - Concomitant medications: review drugs that may increase metformin levels or lactic acid production. - Elderly patients: start with lower doses and monitor tolerance. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metforal can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - MAO‑inhibitors: combined use can lead to severe hypertension. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Alcohol: potentiates risk of lactic acidosis. - Loop diuretics: may affect renal clearance of metformin. - Corticosteroids: can increase blood glucose, requiring dose adjustment. - Beta‑blockers: may mask hypoglycaemia symptoms. - Thyroid hormones: may alter glucose metabolism.